CA2822638C - Cell culture platform for single cell sorting and enhanced reprogramming of ipscs - Google Patents

Cell culture platform for single cell sorting and enhanced reprogramming of ipscs Download PDF

Info

Publication number
CA2822638C
CA2822638C CA2822638A CA2822638A CA2822638C CA 2822638 C CA2822638 C CA 2822638C CA 2822638 A CA2822638 A CA 2822638A CA 2822638 A CA2822638 A CA 2822638A CA 2822638 C CA2822638 C CA 2822638C
Authority
CA
Canada
Prior art keywords
cells
inhibitor
feeder
pluripotent
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2822638A
Other languages
English (en)
French (fr)
Other versions
CA2822638A1 (en
Inventor
Bahram Valamehr
Ramzey ABUJAROUR
Peter Flynn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fate Therapeutics Inc
Original Assignee
Fate Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fate Therapeutics Inc filed Critical Fate Therapeutics Inc
Publication of CA2822638A1 publication Critical patent/CA2822638A1/en
Application granted granted Critical
Publication of CA2822638C publication Critical patent/CA2822638C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081—Purging biological preparations of unwanted cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/148—Transforming growth factor alpha [TGF-a]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/602—Sox-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/603—Oct-3/4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/604—Klf-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/605—Nanog
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/606—Transcription factors c-Myc
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/608—Lin28
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1307—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from adult fibroblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • C12N2509/10—Mechanical dissociation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/52—Fibronectin; Laminin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/54—Collagen; Gelatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA2822638A 2010-12-22 2011-12-19 Cell culture platform for single cell sorting and enhanced reprogramming of ipscs Active CA2822638C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201061426369P 2010-12-22 2010-12-22
US61/426,369 2010-12-22
US201161496991P 2011-06-14 2011-06-14
US61/496,991 2011-06-14
PCT/US2011/065900 WO2012087965A2 (en) 2010-12-22 2011-12-19 Cell culture platform for single cell sorting and enhanced reprogramming of ipscs

Publications (2)

Publication Number Publication Date
CA2822638A1 CA2822638A1 (en) 2012-06-28
CA2822638C true CA2822638C (en) 2021-02-16

Family

ID=46314809

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2822638A Active CA2822638C (en) 2010-12-22 2011-12-19 Cell culture platform for single cell sorting and enhanced reprogramming of ipscs

Country Status (8)

Country Link
US (4) US9732319B2 (cg-RX-API-DMAC7.html)
EP (1) EP2655601A4 (cg-RX-API-DMAC7.html)
JP (6) JP6182456B2 (cg-RX-API-DMAC7.html)
KR (6) KR102160721B1 (cg-RX-API-DMAC7.html)
CN (3) CN106893692B (cg-RX-API-DMAC7.html)
AU (1) AU2011349446C1 (cg-RX-API-DMAC7.html)
CA (1) CA2822638C (cg-RX-API-DMAC7.html)
WO (1) WO2012087965A2 (cg-RX-API-DMAC7.html)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9752124B2 (en) 2009-02-03 2017-09-05 Koninklijke Nederlandse Akademie Van Wetenschappen Culture medium for epithelial stem cells and organoids comprising the stem cells
GB201111244D0 (en) * 2011-06-30 2011-08-17 Konink Nl Akademie Van Wetenschappen Knaw Culture media for stem cells
US8642339B2 (en) 2009-02-03 2014-02-04 Koninklijke Nederlandse Akademie Van Wetenschappen Culture medium for epithelial stem cells and organoids comprising the stem cells
EP2412800A1 (en) 2010-07-29 2012-02-01 Koninklijke Nederlandse Akademie van Wetenschappen Liver organoid, uses thereof and culture method for obtaining them
US9732319B2 (en) 2010-12-22 2017-08-15 Fate Therapeutics, Inc. Cell culture platform for single cell sorting and enhanced reprogramming of iPSCs
WO2013082509A1 (en) 2011-12-01 2013-06-06 The New York Stem Cell Foundation Automated system for producing induced pluripotent stem cells or differentiated cells
US10428309B2 (en) * 2011-12-01 2019-10-01 New York Stem Cell Foundation, Inc. Systems and methods for producing stem cells and differentiated cells
JP6433902B2 (ja) * 2013-01-04 2018-12-05 国立大学法人京都大学 初期化幹細胞
US20150353884A1 (en) * 2013-01-23 2015-12-10 Tokyo Electron Limited Method of subculturing pluripotent stem cells
US10465165B2 (en) 2013-01-28 2019-11-05 Rutgers, The State University Of New Jersey Growth matrices for stem cell propagation in vitro and in tissue regeneration
CN105121632B (zh) * 2013-02-18 2021-08-10 大学健康网络 由多能干细胞生成肝细胞和胆管细胞的方法
US20160115447A1 (en) * 2013-06-11 2016-04-28 President And Fellows Of Harvard College Compositions and methods for improving induced neuron generation
US20160122720A1 (en) * 2013-06-11 2016-05-05 Kyoto University Method of efficiently establishing induced pluripotent stem cells
CN103333920A (zh) * 2013-06-18 2013-10-02 西北农林科技大学 一种建立猪iPS细胞系的培养基及其培养方法
CN104278008B (zh) * 2013-07-12 2020-08-21 北京宏冠再生医学科技有限公司 一种通过小分子化合物处理来制备多潜能干细胞的方法、试剂盒和用途
CN105392881B (zh) * 2013-07-23 2020-09-01 豪夫迈·罗氏有限公司 体细胞基于小分子转化为神经嵴细胞
KR101655383B1 (ko) * 2013-07-27 2016-09-08 고려대학교 산학협력단 소분자 화합물을 포함하는 만능성 줄기세포의 염색체 안정성 유지용 조성물
WO2015064715A1 (ja) * 2013-10-30 2015-05-07 東亞合成株式会社 ゲノム不安定なｉＰＳ細胞の除去方法および該方法に用いられる合成ペプチド
KR101697110B1 (ko) * 2013-11-01 2017-01-18 건국대학교 글로컬산학협력단 세포융합을 통한 줄기세포의 역분화능 측정 방법
CN103667349B (zh) * 2013-11-15 2017-02-15 安徽农业大学 一种高效获取猪诱导性多能干细胞的方法
CN120536341A (zh) * 2014-03-04 2025-08-26 菲特治疗公司 改良的重编程方法和细胞培养平台
WO2015173425A1 (en) 2014-05-16 2015-11-19 Koninklijke Nederlandse Akademie Van Wetenschappen Improved culture method for organoids
US20170114323A1 (en) 2014-06-19 2017-04-27 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
EP3183336B2 (en) * 2014-08-22 2025-07-09 Cambridge Enterprise Limited Resetting pluripotent stem cells
CN105441384B (zh) * 2014-09-26 2021-01-05 北京大学 一种制备动物和人类原始多潜能干细胞的方法，试剂盒及用途
WO2016057649A1 (en) * 2014-10-07 2016-04-14 NuTech Medical, Inc. Mesenchymal stem cell diagnostic testing
GB201421094D0 (en) 2014-11-27 2015-01-14 Koninklijke Nederlandse Akademie Van Wetenschappen Culture medium
GB201421092D0 (en) 2014-11-27 2015-01-14 Koninklijke Nederlandse Akademie Van Wetenschappen Culture medium
CN107614678B (zh) * 2014-12-18 2021-04-30 哈佛学院校长同事会 干细胞来源的β细胞的产生方法及其使用方法
US10626372B1 (en) 2015-01-26 2020-04-21 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
US10738280B2 (en) 2015-03-18 2020-08-11 Ono Pharmaceutical Co., Ltd. Method for producing naïve pluripotent stem cells
CN104707173B (zh) * 2015-04-01 2017-03-29 中国人民解放军总医院 一种三维细胞培养平台、其制备方法及其使用方法
EP3285926B1 (en) 2015-04-21 2022-03-02 General Automation Lab Technologies Inc. Kit and method for high throughput microbiology applications
US10712356B2 (en) 2015-04-21 2020-07-14 General Automation Lab Technologies Inc. Apparatus and method for picking biological sample
CN105624104B (zh) * 2015-06-01 2018-10-12 中国医学科学院血液病医院（血液学研究所） 一种提高人间充质干细胞功能的细胞处理方法
EP3331988B1 (en) 2015-08-07 2023-09-20 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Chemical reprogramming to generate neuronal cells
CA2996582A1 (en) * 2015-08-31 2017-03-09 I Peace, Inc. Pluripotent stem cell manufacturing system and method for producing induced pluripotent stem cells
US11162070B2 (en) 2015-09-08 2021-11-02 FUJIFILM Cellular Dynamics, Inc. MACS-based purification of stem cell-derived retinal pigment epithelium
JP6884354B2 (ja) * 2015-09-08 2021-06-09 大日本住友製薬株式会社 網膜組織の製造方法
CN114807035B (zh) 2015-09-08 2024-02-02 (由卫生与公众服务部部长代表的)美利坚合众国 临床级别视网膜色素上皮细胞的可再现的分化方法
AU2016320991C1 (en) * 2015-09-08 2023-04-06 Healios K.K. Method for producing retinal pigment epithelial cells
CN117737124A (zh) * 2015-10-16 2024-03-22 菲特治疗公司 用于诱导和维护基态多能性的平台
WO2017070333A1 (en) 2015-10-20 2017-04-27 Cellular Dynamics International, Inc. Multi-lineage hematopoietic precursor cell production by genetic programming
CN122146606A (zh) 2015-11-04 2026-06-05 菲特治疗公司 用于诱导造血细胞分化的方法和组合物
US12642852B1 (en) * 2015-11-04 2026-06-02 Fate Therapeutics, Inc. Genomic engineering of pluripotent cells
US20190282624A1 (en) * 2015-11-30 2019-09-19 Beihao Stem Cell And Regenerative Medicine Research Institute Co., Ltd. Improved methods for reprograming non-pluripotent cells into pluripotent stem cells
KR20180114032A (ko) * 2016-01-08 2018-10-17 국립연구개발법인 고쿠리츠간켄큐센터 저분자 화합물에 의한 성숙 간세포로부터의 간 줄기/전구세포의 제작 방법
WO2017134628A1 (en) * 2016-02-03 2017-08-10 The Regents Of The University Of California Methods and compositions for culturing stem cells
GB201603569D0 (en) 2016-03-01 2016-04-13 Koninklijke Nederlandse Akademie Van Wetenschappen Improved differentiation method
CN105950548A (zh) * 2016-05-26 2016-09-21 南京医科大学附属南京儿童医院 一种从间充质干细胞高效获取可跳动有功能心肌细胞的方法
EP3487987A4 (en) 2016-07-19 2020-02-19 Accellta Ltd. CULTURAL MEDIA FOR THE CULTURE OF PLURIPOTENTAL STEM CELLS IN A SUSPENSION
US20190194621A1 (en) * 2016-09-08 2019-06-27 Kyowa Hakko Bio Co., Ltd. Medium for culturing stem cells, method for culturing stem cells, growth promoter for stem cells, and cell composition and method for producing same
JP7134416B2 (ja) * 2016-10-28 2022-09-12 国立研究開発法人国立がん研究センター ヒト肝前駆細胞の調製方法
CN106754729B (zh) * 2016-12-31 2020-03-17 内蒙古赛科星家畜种业与繁育生物技术研究院有限公司 利用Xist Tale抑制性转录因子制备诱导性多能干细胞的方法
US11618883B2 (en) 2017-03-08 2023-04-04 Sumitomo Pharma Co., Ltd. Method for producing retinal pigment epithelial cells
CN110891967B (zh) 2017-04-18 2025-03-14 富士胶片细胞动力公司 抗原特异性免疫效应细胞
JP6647545B2 (ja) * 2017-05-02 2020-02-14 剛士 田邊 医薬品組成物及び化粧品組成物
EP3406712A1 (en) 2017-05-26 2018-11-28 Fundación Centro Nacional De Investigaciones Oncológicas Carlos III Method for expanding stemness and differentiation potential of pluripotent cells
US12247226B2 (en) 2017-10-11 2025-03-11 Fate Therapeutics, Inc. Cellular reprogramming using temporal and transient plasmid vector expression system
JP6680742B2 (ja) 2017-10-31 2020-04-15 大研医器株式会社 磁性粒子収集方法及び試験セット
US20190167724A1 (en) * 2017-12-04 2019-06-06 Caire Medical-Biotechnology International Co. Neuroprotective composition, preparation process thereof and medical uses thereof
GB201721615D0 (en) 2017-12-21 2018-02-07 Koninklijke Nederlandse Akademie Van Wetenschappen Immune cell organoid co-cultures
CN108265025A (zh) * 2017-12-28 2018-07-10 安徽中盛溯源生物科技有限公司 一种人类诱导多能干细胞的重编程培养基
EP3747996A4 (en) * 2018-01-31 2021-03-17 FUJIFILM Corporation METHOD OF MANUFACTURING CELLS
JP7097050B2 (ja) * 2018-03-19 2022-07-07 国立大学法人京都大学 効率的な人工多能性幹細胞の樹立方法
DK3810758T3 (da) * 2018-06-20 2023-10-16 Biolamina Ab Metoder og sammensætninger til fremstilling af retina pigment epitelceller
WO2020027094A1 (ja) * 2018-07-31 2020-02-06 サイアス株式会社 ｉＰＳ細胞を介して再生Ｔ細胞集団を製造する方法
AU2019334666B2 (en) * 2018-09-07 2023-11-02 Cha Biotech Co., Ltd. Medium for direct differentiation of pluripotent stem cell-derived mesenchymal stem cell, method for preparing mesenchymal stem cell by using same, and mesenchymal stem cell prepared thereby
EP3868870B1 (en) * 2018-10-15 2025-12-03 Evia Life Sciences Inc. Method for producing stem/precursor cells, by using low molecular weight compound, from cells derived from endodermal tissue or organ
GB201819224D0 (en) 2018-11-26 2019-01-09 Koninklijke Nederlandse Akademie Van Wetenschappen Hepatocyte expansion methods
JP7692610B2 (ja) * 2019-02-26 2025-06-16 国立大学法人東北大学 ｉＰＳ細胞を用いた骨芽細胞塊の作製法
CN109938987B (zh) * 2019-03-15 2024-06-04 首都医科大学宣武医院 放置于口腔内部的抽动障碍治疗器
US12618755B2 (en) 2019-03-20 2026-05-05 Dany Adams Methods and systems for assessing bioelectric patterns
EP3969571A4 (en) 2019-05-14 2023-05-24 Aleph Farms Ltd. PLURIPOTENTE CELL AGGREGATES AND THEIR USE
CN112301052A (zh) 2019-08-01 2021-02-02 浙江霍德生物工程有限公司 一种通过体细胞重编程制备诱导多功能干细胞的方法
CN115103903A (zh) * 2019-09-19 2022-09-23 西北大学 用于人诱导型多能干细胞的具成本效益的培养基和操作方案
US20210395698A1 (en) * 2020-06-22 2021-12-23 Life Technologies Corporation Methods and compositions for cultivating pluripotent cell suspensions
JP2023544324A (ja) * 2020-10-02 2023-10-23 フェイト セラピューティクス，インコーポレイティド 人工多能性幹細胞のための改善されたリプログラミング、維持及び保存
GB202115676D0 (en) * 2021-11-01 2021-12-15 Icahn School Med Mount Sinai Methods and compositions for bat ipsc preparation and use
EP4170018A1 (en) * 2021-10-20 2023-04-26 Roslin Technologies Limited Ipsc induction and progeny derivation
WO2023067090A1 (en) * 2021-10-20 2023-04-27 Roslin Technologies Limited Ipsc induction and progeny derivation
CN114591894B (zh) * 2022-02-28 2024-01-09 中国人民解放军总医院 一种皮肤多能前体干细胞的制备方法及其应用
EP4495229A4 (en) * 2022-03-14 2025-12-24 Space F Corp MEDIUM COMPOSITION FOR THE CULTURE OF PORCINE PLURIPOTENT STEM CELLS
WO2024102954A1 (en) 2022-11-10 2024-05-16 Massachusetts Institute Of Technology Activation induced clipping system (aics)
WO2025152036A1 (en) * 2024-01-16 2025-07-24 Chiou Guang Yuh System and method for increasing the transduction capability and reprogramming efficiency in targeting cells and tissues
WO2025235862A1 (en) 2024-05-10 2025-11-13 Inndura Therapeutics Inc. A modified immune cell receptor comprising a target-binding domain and the extracellular domain of cd16a
WO2026096366A1 (en) * 2024-10-28 2026-05-07 Bluerock Therapeutics Lp Compositions and methods for determination of pluripotent stem cell differentiability
WO2026107113A1 (en) 2024-11-12 2026-05-21 Calidi Biotherapeutics (Nevada), Inc. MODIFIED CELLS FOR PROGRAMMING EXTRA ENVELOPED VIRUSES (EEVs) AND THEIR USE FOR PRODUCING THE EEVs, THE PROGRAMMED EEVs AND USES THEREOF

Family Cites Families (155)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
IE66205B1 (en) 1990-06-14 1995-12-13 Paul A Bartlett Polypeptide analogs
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
US5384253A (en) 1990-12-28 1995-01-24 Dekalb Genetics Corporation Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
ES2148179T3 (es) 1991-09-06 2000-10-16 Yoshitomi Pharmaceutical Compuesto de 4-amino(alquil)ciclohexan-1-carboxamida y uso del mismo.
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5702932A (en) 1992-07-20 1997-12-30 University Of Florida Microinjection methods to transform arthropods with exogenous DNA
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
WO1995003402A1 (en) 1993-07-22 1995-02-02 Merck & Co., Inc. EXPRESSION OF HUMAN INTERLEUKIN-1β IN A TRANSGENIC ANIMAL
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5593853A (en) 1994-02-09 1997-01-14 Martek Corporation Generation and screening of synthetic drug libraries
US5539083A (en) 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
US5656610A (en) 1994-06-21 1997-08-12 University Of Southern California Producing a protein in a mammal by injection of a DNA-sequence into the tongue
US5525735A (en) 1994-06-22 1996-06-11 Affymax Technologies Nv Methods for synthesizing diverse collections of pyrrolidine compounds
US5549974A (en) 1994-06-23 1996-08-27 Affymax Technologies Nv Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
WO1997000271A1 (en) 1995-06-14 1997-01-03 The Regents Of The University Of California Novel high affinity human antibodies to tumor antigens
US5569588A (en) 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5780448A (en) 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish
GB9807935D0 (en) 1998-04-14 1998-06-10 Univ Edinburgh Lineage specific cells and progenitor cells
US5945100A (en) 1996-07-31 1999-08-31 Fbp Corporation Tumor delivery vehicles
PT956865E (pt) 1996-08-12 2007-07-30 Mitsubishi Pharma Corp Medicamentos compreendendo inibidores da rho cinase.
US5981274A (en) 1996-09-18 1999-11-09 Tyrrell; D. Lorne J. Recombinant hepatitis virus vectors
WO1998050048A1 (en) 1997-05-07 1998-11-12 Pharma Mar, S.A. Aplidine as an l-type calcium channel enhancer
CA2292339A1 (en) 1997-06-13 1998-12-17 Ludwig Institute For Cancer Research Smad6 and uses thereof
ES2229515T3 (es) 1997-07-01 2005-04-16 Warner-Lambert Company Llc Derivados 4-bromo o 4-yodo del acido fenilamino benzhidroxamico y su uso como inhibidores de la mek.
US5994624A (en) 1997-10-20 1999-11-30 Cotton Incorporated In planta method for the production of transgenic plants
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US20060263382A1 (en) 1998-06-20 2006-11-23 Richard Hotchkiss Membrane-permeant peptide complexes for treatment of sepsis
EP1100872A1 (en) 1998-07-24 2001-05-23 Carnegie Institution Of Washington Method for maintenance and propagation of germline stem cells using members of the tgf-beta family of growth factors
GB9819912D0 (en) 1998-09-11 1998-11-04 Univ Edinburgh Propagation and/or derivation of embryonic stem cells
CA2350234A1 (en) 1999-01-07 2000-07-13 Alexander James Bridges Treatment of asthma with mek inhibitors
US6703420B1 (en) 1999-03-19 2004-03-09 Bristol-Myers Squibb Pharma Company Amino-thio-acrylonitriles as MEK inhibitors
WO2000078351A1 (en) 1999-06-18 2000-12-28 Mitsubishi Pharma Corporation Osteogenesis promoters
US6730293B1 (en) 1999-08-24 2004-05-04 Cellgate, Inc. Compositions and methods for treating inflammatory diseases of the skin
WO2001017562A1 (fr) 1999-09-02 2001-03-15 Yamanouchi Pharmaceutical Co., Ltd. Agents promoteurs de l'osteogenese
US20020142457A1 (en) 1999-12-28 2002-10-03 Akihiro Umezawa Cell having the potentiality of differentiation into cardiomyocytes
US6692736B2 (en) 2000-03-24 2004-02-17 Cell Genesys, Inc. Cell-specific adenovirus vectors comprising an internal ribosome entry site
AU7349801A (en) 2000-07-19 2002-01-30 Warner Lambert Co Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
WO2008108741A1 (en) 2007-03-07 2008-09-12 S*Bio Pte Ltd Combination of benzimidazole anti-cancer agent and a second anti-cancer agent
PE20020958A1 (es) 2001-03-23 2002-11-14 Bayer Corp Inhibidores de la rho-quinasa
HN2002000067A (es) 2001-03-23 2003-10-24 Bayer Healthcare Llc Inhibidores de la rho - quinasa.
WO2002088346A2 (en) 2001-05-01 2002-11-07 National Research Council Of Canada A system for inducible expression in eukaryotic cells
WO2003027277A1 (en) 2001-09-21 2003-04-03 Japan Science And Technology Corporation Method of screening reporgramming factor, reprogramming factor screened by the method, method of using the reprogramming factor, method of differentiating undifferentiated fused cells and method of constructing cell, tissues and organs
SI1456380T1 (sl) 2001-11-02 2012-11-30 Giuliani Int Ltd Smad inhibitorji za zdravljenje cns bolezni
EP1465900B1 (en) 2002-01-10 2008-05-14 Bayer HealthCare AG Rho-kinase inhibitors
MXPA04007191A (es) 2002-01-23 2005-03-31 Bayer Pharmaceuticals Corp Derivados de pirimidina como inhibidores de rho-quinasa.
CA2473910C (en) 2002-01-23 2011-03-15 Bayer Pharmaceuticals Corporation Pyrimidine derivatives as rho-kinase inhibitors
ATE306810T1 (de) 2002-03-05 2005-11-15 Artemis Pharmaceuticals Gmbh Durch inzucht erzeugte von embryonalen stammzellen abgeleitete mäuse
SG2013013339A (en) 2002-03-13 2014-12-30 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
EP1500643A4 (en) 2002-04-03 2007-03-28 Dainippon Sumitomo Pharma Co benzamidine
GB0210539D0 (en) 2002-05-08 2002-06-19 Univ Edinburgh Control of es cell self renewal and lineage specification, and medium therefor
ES2273047T3 (es) 2002-10-28 2007-05-01 Bayer Healthcare Ag Fenilaminopirimidinas sustituidas con heteroariloxi como inhibidores de rho-cinasa.
EP1562601A1 (en) 2002-11-15 2005-08-17 Warner-Lambert Company LLC Combination chemotherapy comprising a mek inhibitor and capecitabine for treating cancer
PT1572984E (pt) * 2002-12-16 2016-06-03 Technion Res & Dev Foundation Sistema de cultura para células estaminais embrionárias humanas sem células alimentadoras e sem xeno
WO2004072068A1 (en) 2003-02-10 2004-08-26 Amgen Inc. Vanilloid receptor ligands and their use in treatments
AU2003901099A0 (en) 2003-03-11 2003-03-27 Es Cell International Pte Ltd. Methods of inducing differentiation of stem cells
US20050075276A1 (en) 2003-03-14 2005-04-07 Christopher Rudd Use of inhibitors of glycogen synthase-3 to augment CD28 dependent -T-cell responses
US20070010008A1 (en) 2005-06-29 2007-01-11 Tissuetech, Inc. Ex vivo expansion of primary animal cells
US20060222657A1 (en) 2003-06-20 2006-10-05 Dowdy Steven F Polypeptide transduction and fusogenic peptides
BRPI0414961A (pt) 2003-10-03 2006-11-07 Keiichi Fukuda processo de indução da diferenciação de células tronco em células do miocárdio
TWI344961B (en) 2003-10-15 2011-07-11 Ube Industries Novel indazole derivative
CA2542276A1 (en) 2003-10-16 2005-04-28 The University Court Of The University Of Edinburgh Control of es cell self-renewal and lineage specification, and medium therefor
WO2005049812A1 (en) 2003-11-19 2005-06-02 Australian Stem Cell Centre Limited Methods for producing blood products from pluripotent cells in cell culture
KR101190912B1 (ko) 2003-11-19 2012-10-12 어레이 바이오파마 인크. Ｍｅｋ의 헤테로시클릭 억제제 및 그의 사용 방법
US20070269412A1 (en) 2003-12-02 2007-11-22 Celavie Biosciences, Llc Pluripotent cells
JP2007519754A (ja) 2004-01-30 2007-07-19 スミスクライン ビーチャム コーポレーション 化合物
AU2005241009A1 (en) 2004-04-21 2005-11-17 Mcmaster University Myosin light chain kinase inhibitors and their use
US8187878B2 (en) 2004-08-13 2012-05-29 University Of Georgia Research Foundation, Inc. Methods for increasing definitive endoderm differentiation of pluripotent human embryonic stem cells with PI-3 kinase inhibitors
WO2006026473A2 (en) 2004-08-25 2006-03-09 University Of Georgia Research Foundation, Inc. METHODS AND COMPOSITIONS UTILIZING MYC AND GSK3ß TO MANIPULATE THE PLURIPOTENCY OF EMBRYONIC STEM CELLS
US20060182724A1 (en) 2005-02-15 2006-08-17 Riordan Neil H Method for expansion of stem cells
TWI441637B (zh) 2005-05-18 2014-06-21 Array Biopharma Inc Ｍｅｋ雜環抑制劑及其使用方法
KR101004634B1 (ko) 2005-08-01 2011-01-04 뉴포텐셜, 인크. 잠재력이 복원된 리프로그래밍된 세포의 제조
WO2007030693A2 (en) 2005-09-08 2007-03-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods for promoting stem cell proliferation and survival
US8217042B2 (en) 2005-11-11 2012-07-10 Zentaris Gmbh Pyridopyrazines and their use as modulators of kinases
EP2206724A1 (en) 2005-12-13 2010-07-14 Kyoto University Nuclear reprogramming factor
US20090227032A1 (en) 2005-12-13 2009-09-10 Kyoto University Nuclear reprogramming factor and induced pluripotent stem cells
GB0601538D0 (en) 2006-01-26 2006-03-08 Univ Birmingham Epigenetic analysis
EP1992360A4 (en) 2006-02-01 2010-02-17 Univ Tokyo COMMON USE OF A TGF BETA SIGNAL HEMMER AND AN ANTITUMORAL AGENT
US7541186B2 (en) 2006-02-22 2009-06-02 University Of Washington Method of generating human retinal progenitors from embryonic stem cells
GB0615327D0 (en) 2006-03-30 2006-09-13 Univ Edinburgh Culture medium containing kinase inhibitors and uses thereof
WO2007113505A2 (en) 2006-03-30 2007-10-11 The University Court Of The University Of Edinburgh Culture medium containing kinase inhibitors. and uses thereof
US8741643B2 (en) 2006-04-28 2014-06-03 Lifescan, Inc. Differentiation of pluripotent stem cells to definitive endoderm lineage
GB2452186B (en) 2006-05-02 2011-01-26 Wisconsin Alumni Res Found Method of differentiating stem cells into cells of the endoderm and pancreatic lineage
US20070298496A1 (en) * 2006-06-23 2007-12-27 Hung-Chih Kuo Method of deriving pluripotent stem cells from a single blastomere
WO2008005268A1 (en) 2006-06-30 2008-01-10 Schering Corporation Substituted piperidines that increase p53 activity and the uses thereof
CA2657227A1 (en) 2006-07-14 2008-01-17 Novartis Ag Pyrimidine derivatives as alk-5 inhibitors
US20080020014A1 (en) 2006-07-19 2008-01-24 Paul Consigny Implantable devices containing nuclear receptor ligands for the treatment of vascular and related disorders
JP2008099662A (ja) * 2006-09-22 2008-05-01 Institute Of Physical & Chemical Research 幹細胞の培養方法
ZA200901914B (en) * 2006-09-22 2010-06-30 Riken Stem cell culture medium and method
GB0622395D0 (en) 2006-11-09 2006-12-20 Univ Cambridge Tech Methods relating to pluripotent cells
SE0950586L (sv) 2007-01-17 2009-08-13 Wisconsin Alumni Res Found Förbättrad odling av stamceller
WO2008088882A2 (en) 2007-01-19 2008-07-24 The J. David Gladstone Institutes Methods of generating cardiomyocytes
EP2126045A4 (en) 2007-01-30 2010-05-26 Univ Georgia EARLY MESODERM CELLS, STABLE POPULATION OF MESENDODERM CELLS WITH THE ABILITY TO GENERATE ENDODERM AND MESODERM CELL LINES AND MULTIPOTENTIAL MIGRATION CELLS
WO2008105630A1 (en) 2007-02-27 2008-09-04 Procell Therapeutics Inc. Combined use of cell permeable nanog and oct4 for increasing self-renewal and suppressing differentiation of stem cells
WO2008126932A2 (en) 2007-04-09 2008-10-23 Riken Epigenetical regulation of brain plasticity
CA2684460C (en) 2007-04-18 2017-01-03 Hadasit Medical Research Services & Development Limited Stem cell-derived retinal pigment epithelial cells
US7878210B2 (en) 2007-06-04 2011-02-01 Philip Morris Usa Inc. Cellulose acetate fiber modification
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
US9213999B2 (en) 2007-06-15 2015-12-15 Kyoto University Providing iPSCs to a customer
AU2008272949B2 (en) 2007-06-29 2014-05-15 FUJIFILM Cellular Dynamics, Inc. Automated method and apparatus for embryonic stem cell culture
US20120282229A1 (en) 2007-08-01 2012-11-08 Christian Kannemeier Non-viral delivery of transcription factors that reprogram human somatic cells into a stem cell-like state
WO2009032194A1 (en) 2007-08-31 2009-03-12 Whitehead Institute For Biomedical Research Wnt pathway stimulation in reprogramming somatic cells
AU2008297024B2 (en) 2007-10-31 2014-08-28 Kyoto University Nuclear reprogramming method
US20110151447A1 (en) 2007-11-06 2011-06-23 Children's Medical Center Corporation Method to produce induced pluripotent stem (ips) cells from non-embryonic human cells
JP4604076B2 (ja) 2007-11-07 2010-12-22 国立大学法人静岡大学 燃料電池用電解質膜
EP2227540A4 (en) 2007-11-29 2011-11-02 Children S Hospital Of Orange County DIFFERENTIATION OF HUMAN CELLS
AU2008329563A1 (en) 2007-11-30 2009-06-04 Cytomatrix Pty Ltd Methods of inducing pluripotency involving Oct4 protein
EP2227241A1 (en) 2007-11-30 2010-09-15 Cytomatrix PTY LTD Methods of inducing pluripotency involving sox2 protein
JP5951254B2 (ja) 2008-03-17 2016-07-13 ザ スクリプス リサーチ インスティテュート 人工多能性幹細胞を作製するための化学的手法と遺伝的手法の組み合わせ法
EP2268796A1 (en) 2008-03-17 2011-01-05 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Vectors and methods for generating vector-free induced pluripotent stem (ips) cells using site-specific recombination
CN101550406B (zh) 2008-04-03 2016-02-10 北京大学 制备多潜能干细胞的方法,试剂盒及用途
KR101685209B1 (ko) 2008-07-30 2016-12-09 고쿠리츠 다이가쿠 호진 교토 다이가쿠 유도된 다능성 줄기 세포의 효율적인 확립 방법
WO2010019569A1 (en) * 2008-08-12 2010-02-18 Cellular Dynamics International. Inc. Methods for the production of ips cells
US8298825B1 (en) 2008-08-25 2012-10-30 The General Hospital Corporation TGF-beta receptor inhibitors to enhance direct reprogramming
CN108342353B (zh) * 2008-11-04 2022-01-11 韦尔赛特公司 干细胞聚集体悬浮组合物及其分化方法
AU2009322346B2 (en) 2008-12-03 2015-07-02 The Scripps Research Institute Stem cell cultures
CA2688804A1 (en) 2008-12-17 2010-06-17 The Uab Research Foundation Polycistronic vector for human induced pluripotent stem cell production
SG172160A1 (en) 2008-12-17 2011-07-28 Scripps Research Inst Generation and maintenance of stem cells
US20120122212A1 (en) 2009-03-06 2012-05-17 Marica Grskovic Tgf-beta pathway inhibitors for enhancement of cellular reprogramming of human cells
US20120128655A1 (en) 2009-04-03 2012-05-24 The Mclean Hospital Corporation Induced pluripotent stem cells
AU2010236632A1 (en) 2009-04-13 2011-09-15 The Regents Of The University Of California Methods and compositions for stem cell cultures
WO2010138750A2 (en) * 2009-05-27 2010-12-02 The Salk Institute For Biological Studies Generation of genetically corrected disease-free induced pluripotent stem cells
JP5777113B2 (ja) 2009-05-29 2015-09-09 学校法人慶應義塾 人工多能性幹細胞のクローンの選択方法
US8524498B2 (en) 2009-05-29 2013-09-03 The General Hospital Corporation Methods and compositions for homologous recombination in human cells
US8900871B2 (en) 2009-08-07 2014-12-02 Kyoto University Method of producing induced pluripotent stem cells using inhibitors of P53
MX389666B (es) * 2009-10-16 2025-03-19 Scripps Research Inst Induccion de celulas pluripotentes.
LT2494039T (lt) * 2009-10-31 2019-07-25 Genesis Technologies Limited Ląstelių perprogramavimo būdai ir jų panaudojimas
KR101775926B1 (ko) 2009-11-04 2017-09-07 셀룰러 다이내믹스 인터내셔널, 인코포레이티드 화학 물질을 이용한 에피솜 재프로그래밍
WO2011058558A2 (en) 2009-11-12 2011-05-19 Technion Research & Development Foundation Ltd. Culture media, cell cultures and methods of culturing pluripotent stem cells in an undifferentiated state
US9005967B2 (en) 2010-01-22 2015-04-14 Kyoto University Myc variants improve induced pluripotent stem cell generation efficiency
AU2011218041B2 (en) 2010-02-17 2015-12-17 Lineage Cell Therapeutics, Inc. Methods for telomere length and genomic DNA quality control analysis in pluripotent stem cells
EP2542669B1 (en) 2010-03-05 2015-01-21 Texas Heart Institute Ets2 and mesp1 generate cardiac progenitors from fibroblasts
CA2800498C (en) 2010-03-31 2021-11-16 The Scripps Research Institute Reprogramming cells
JPWO2011158852A1 (ja) 2010-06-15 2013-08-19 国立大学法人 東京大学 誘導型多能性幹細胞の製造方法
US20110306516A1 (en) 2010-06-15 2011-12-15 The New York Stem Cell Foundation Methods for producing induced pluripotent stem cells
CA2802249A1 (en) * 2010-06-15 2011-12-22 Cellular Dynamics International, Inc. Generation of induced pluripotent stem cells from small volumes of peripheral blood
EP2601289B1 (en) * 2010-08-04 2017-07-12 Cellular Dynamics International, Inc. Reprogramming immortalized b cells
US9732319B2 (en) 2010-12-22 2017-08-15 Fate Therapeutics, Inc. Cell culture platform for single cell sorting and enhanced reprogramming of iPSCs
WO2013070852A2 (en) 2011-11-08 2013-05-16 Emory University Compounds and compositions used to epigenetically transform cells and methods related thereto
WO2013086436A1 (en) 2011-12-08 2013-06-13 Fred Hutchinson Cancer Research Center Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells
WO2013159103A1 (en) 2012-04-20 2013-10-24 Whitehead Institute For Biomedical Research Programming and reprogramming of cells
EP2853590B1 (en) 2012-05-22 2018-11-07 The University of Tokyo Method for producing antigen-specific t cells
US9166832B1 (en) 2013-10-04 2015-10-20 Altera Corporation Methods and apparatus for decision feedback equalization adaptation
CN120536341A (zh) 2014-03-04 2025-08-26 菲特治疗公司 改良的重编程方法和细胞培养平台
CN117737124A (zh) 2015-10-16 2024-03-22 菲特治疗公司 用于诱导和维护基态多能性的平台
US12642852B1 (en) 2015-11-04 2026-06-02 Fate Therapeutics, Inc. Genomic engineering of pluripotent cells

Also Published As

Publication number Publication date
CN103380212A (zh) 2013-10-30
US10844356B2 (en) 2020-11-24
KR102703637B1 (ko) 2024-09-05
JP2017158585A (ja) 2017-09-14
US12415989B2 (en) 2025-09-16
KR20190049918A (ko) 2019-05-09
KR101975688B1 (ko) 2019-05-07
JP2023138509A (ja) 2023-10-02
KR20170064555A (ko) 2017-06-09
EP2655601A2 (en) 2013-10-30
JP7350127B2 (ja) 2023-09-25
JP7606569B2 (ja) 2024-12-25
JP2014501108A (ja) 2014-01-20
AU2011349446C1 (en) 2016-01-21
CN106893692B (zh) 2021-11-26
JP7513412B2 (ja) 2024-07-09
KR20140063501A (ko) 2014-05-27
CA2822638A1 (en) 2012-06-28
AU2011349446B2 (en) 2015-09-03
KR20200113286A (ko) 2020-10-06
US20210079359A1 (en) 2021-03-18
KR102160721B1 (ko) 2020-09-29
JP2020108399A (ja) 2020-07-16
CN103380212B (zh) 2017-04-05
KR20230006038A (ko) 2023-01-10
KR20210097834A (ko) 2021-08-09
KR102482184B1 (ko) 2022-12-28
US20140220681A1 (en) 2014-08-07
US20170362569A1 (en) 2017-12-21
WO2012087965A2 (en) 2012-06-28
CN114164167B (zh) 2025-02-21
JP6682474B2 (ja) 2020-04-15
US20260035672A1 (en) 2026-02-05
CN106893692A (zh) 2017-06-27
US9732319B2 (en) 2017-08-15
CN114164167A (zh) 2022-03-11
WO2012087965A3 (en) 2012-10-04
EP2655601A4 (en) 2014-09-10
JP6182456B2 (ja) 2017-08-23
AU2011349446A1 (en) 2013-04-11
JP2022097516A (ja) 2022-06-30
JP2025039573A (ja) 2025-03-21

Similar Documents

Publication Publication Date Title
US20260035672A1 (en) Cell culture platform for single cell sorting and enhanced reprogramming of ipscs
US12618049B2 (en) Reprogramming methods and cell culture platforms
HK40068498B (en) Cell culture platform for single cell sorting and enhanced reprogramming of ipscs
HK40068498A (zh) 用於单细胞分选与增强ipsc重新编程的细胞培养平台
HK1239743A1 (en) Cell culture platform for single cell sorting and enhanced reprogramming of ipscs
HK1239743B (en) Cell culture platform for single cell sorting and enhanced reprogramming of ipscs
HK1191049A (en) Cell culture platform for single cell sorting and enhanced reprogramming of ipscs
HK1191049B (en) Cell culture platform for single cell sorting and enhanced reprogramming of ipscs

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20161130